PRODUCT INFORMATIONPRODUCT INFORMATION

Bimeda® a division of the Cross Vetpharm Group Ltd.Broomhill Road I Tallaght I Dublin 24 I Ireland Tel: 1850-515253 Fax: 01 451 5803 Web: www.bimeda.ie

BOVISEALBismuth Subnitrate 2.6g

BENEFITS• Seals the teat from the moment of drying off until calving• Protection for the entire dry cow period thus reducing cases of dry cow mastitis• Less cases of mastitis in the next lactation• Proven efficacy in mastitis prevention through trial work and customer satisfaction• Nil milk withdrawal when used on it’s own• Can be combined with any other dry cow tube for a synergistic approach to mastitis prevention and control

PACKAGING

1BOV010 120 SYRINGES 1

BOVISEAL

LIST NO. UNIT PACKAGE CASE SIZE

See reverse side for full indications, administrationand dosage.

PRODUCT INFORMATIONTECHNICAL INFORMATION

Bimeda® a division of the Cross Vetpharm Group Ltd.Broomhill Road I Tallaght I Dublin 24 I Ireland Tel: 1850-515253 Fax: 01 451 5803 Web: www.bimeda.ie

BOVISEAL NAPresentationBoviseal is an off-white smooth paste. It is presented in syringes each containing 4 g intramammary infusion containing 65% Bismuth Subnitrate, in a mineraloil vehicle.

UsesBoviseal is indicated for the prevention of new intramam-mary infections throughout the dry period. This results in a reduction in the incidence of sub clinical mastitis in cows at calving, and of clinical mastitis in the dry period and the subsequent lactation (for at least 60 days after calving).It is recommended that Boviseal be used as part of a herd approach to dry cow management and mastitis control. Cows considered likely to be free of sub clinical mastitis should be given Boviseal at drying off according to the criteria below. Other animals should be managed in accordance with an approved mastitis control plan or specific veterinary advice.

For practical purposes, selection criteria may be based on the mastitis and cell count history of individual cows, or recognised tests for the detection of sub clinical mastitis or bacteriological sampling. It is particularly important that, prior to treatment, an individual cell count be obtained from any cow with a history of clinical mas-titis during the previous lactation. As a guide, cows with an average cell count less than 200,000 cells/ml before drying off may be given Boviseal. A minor increase (cell count up to 250,000 cells/ml) during the last 4 weeks before drying off is normal and may be ignored. In case of doubt, veterinary advice should be sought

Dosage and AdministrationDosageOne syringe into each udder quarter immediately after the last milking of the lactation (at drying off).

AdministrationAt drying off the teat should be thoroughly cleaned and disinfected, and it should be allowed to dry before infu-sion; this is essential, as Boviseal possesses no antimi-crobial activity.

Care should also be taken to avoid contamination of the syringe nozzle. Insert nozzle into the teat and apply gentle and continuous pressure until the paste is expressed. Do not massage the teat or udder after infusion of the product. It is advisable to use an appropriate teat disinfectant following the infusion.

Contra-indications, Warnings, etc.Not intended for use in cows with a suspected or confirmed intramammary infection at drying off.

Do not use in the lactating cow. If lactating cows are accidentally infused the seal can easily be stripped out manually and no additional precautions are needed.If a sealed quarter develops clinical mastitis the affected quarter should be stripped out manually before appropriate antibacterial therapy is instituted.For single use only.

Withdrawal PeriodsMeat and offal: zero daysMilk: zero days

Pharmaceutical PrecautionsKeep out of the reach and sight of children.For animal treatment only.

Legal Category LM

Package Quantities 120 syringes.

Further InformationMost of the seal comes out at the first stripping, suckling or milking after calving, but small amounts may occasionally be seen for a few days as flecks on the filter. Boviseal can be differentiated from mastitis by its texture.Under cold conditions the product may be warmed to room temperature in a warm environment, to aid syringeability. Individual tubes must not be placed in warm water.Any unused product or waste material should be disposed of in accordance with national requirements.

Operator Warnings No special precautions.

VPA No. 10960/49/1